A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Inclusion criteria

• Have overweight or obesity, but are otherwise overtly healthy.
• Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)/square meter (m²), inclusive.
• Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.

Exclusion criteria

• Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of the following at screening

• A fasting plasma glucose concentration greater than or equal to 126 milligrams (mg)/deciliter (dL) or 7.0 millimoles (mmol)/liter (L), or
• Hemoglobin A1C (HbA1c) greater than or equal to 6.5% or 48 mmol/mole (mol).
• Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, and bipolar disorder, within the last 2 years.
• Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, or GIP/GLP-1/glucagon receptor agonist within 60 days or 5 half-lives, whichever is longer, prior to screening.
• Are in the judgment of the investigator, actively suicidal or deemed to be at significant risk for suicide.